title: Expression of human beta defensins (HBDs) 1, 2 and 3 in gingival crevicular fluid of patients affected by localized aggressive periodontitis.
abstract: OBJECTIVE
  To study the effect of nonsurgical periodontal therapy on the expression frequencies of human beta-defensin (HBD)-1, -2, and -3 in the gingival crevicular fluid (GCF) of patients affected by localized aggressive periodontitis.
  
  
  METHODS
  Twenty patients affected by localized aggressive periodontitis (age range, 20-35 years) and 20 healthy subjects (age range, 21-37 years) were examined with clinical periodontal parameters and radiographic examination with the long-cone parallel technique. All periodontitis patients underwent nonsurgical periodontal therapy combined with doxycycline treatment and a maintenance program (including brushing with regular toothpaste). GCF samples were collected from patients and healthy control subjects at baseline as well as 3 months after periodontal therapy for the patient group.
  
  
  RESULTS
  In the patient group, the expression frequencies of HBD-1, -2, and -3 mRNA at baseline were 30%, 85%, and 35%, respectively, which changed after periodontal therapy to 80%, 45%, and 85%, respectively (all P < 0.001). In the healthy control subjects, the expression frequencies were 95%, 40%, and 95% for HBD-1, -2, and -3, respectively, which were different from those of diseased patients at baseline (all P < 0.001).
  
  
  CONCLUSIONS
  The appropriate expression of HBD peptides in health and disease may contribute to the maintenance of periodontal homeostasis, possibly through its antimicrobial effects and the promotion of adaptive immune responses.
authors: Department of Oral Medicine, Periodontology and Oral Diagnosis, Faculty of Dental Medicine, Minia University, Egypt.
authors: Mohamed Abdelmoniem
authors: MA
authors: Ebrahem
keywords: Aggressive periodontitis; Beta defensins; PCR
references: Oral Microbiol Immunol. 2008 Aug;23(4):328-35
references: 18582333
references: Infect Immun. 1987 Mar;55(3):568-71
references: 3643886
references: J Immunol. 2003 Sep 15;171(6):3262-9
references: 12960356
references: J Periodontal Res. 2001 Oct;36(5):285-94
references: 11585115
references: Cell Tissue Res. 2001 Nov;306(2):257-64
references: 11702237
references: Pharmacol Ther. 1995 May;66(2):191-205
references: 7667395
references: J Clin Microbiol. 2005 Nov;43(11):5721-32
references: 16272510
references: Oral Microbiol Immunol. 2009 Oct;24(5):417-22
references: 19702957
references: Periodontol 2000. 1997 Jun;14:216-48
references: 9567973
references: Springer Semin Immunopathol. 1992;13(3-4):265-79
references: 1411898
references: FEBS Lett. 1993 Jan 4;315(2):187-92
references: 8417977
references: J Immunol Methods. 2001 Oct 1;256(1-2):65-76
references: 11516756
references: Immunol Cell Biol. 2008 Nov-Dec;86(8):643-9
references: 18711400
references: FEBS Lett. 1996 Nov 4;396(2-3):319-22
references: 8915011
references: Nat Rev Immunol. 2003 Sep;3(9):710-20
references: 12949495
references: Am J Pathol. 1998 May;152(5):1247-58
references: 9588893
references: Periodontol 2000. 1997 Jun;14:12-32
references: 9567964
references: Infect Immun. 1999 Jun;67(6):2740-5
references: 10338476
references: FEBS Lett. 1995 Jul 17;368(2):331-5
references: 7628632
references: Future Microbiol. 2010 Jan;5(1):99-113
references: 20020832
references: Ann Periodontol. 1999 Dec;4(1):1-6
references: 10863370
references: J Clin Periodontol. 1999 Aug;26(8):531-40
references: 10450814
references: J Periodontal Res. 2005 Dec;40(6):474-81
references: 16302926
references: J Periodontal Res. 2004 Aug;39(4):221-7
references: 15206914
references: FASEB J. 2001 Aug;15(10):1819-21
references: 11481241
references: J Biol Chem. 2001 Feb 23;276(8):5707-13
references: 11085990
references: Infect Immun. 1997 Jun;65(6):2389-95
references: 9169779
references: J Periodontol. 2005 Feb;76(2):289-94
references: 15974855